Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells

A. Tanaka, H. Nishikawa, Shinsuke Noguchi, D. Sugiyama, Hiromasa Morikawa, Yoshiko Takeuchi, D. Ha, Naoya Shigeta, T. Kitawaki, Y. Maeda, Takuro Saito, Yoshinori Shinohara, Y. Kameoka, K. Iwaisako, F. Monma, K. Ohishi, J. Karbach, E. Jäger, K. Sawada, N. Katayama, N. Takahashi, S. Sakaguchi
{"title":"Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells","authors":"A. Tanaka, H. Nishikawa, Shinsuke Noguchi, D. Sugiyama, Hiromasa Morikawa, Yoshiko Takeuchi, D. Ha, Naoya Shigeta, T. Kitawaki, Y. Maeda, Takuro Saito, Yoshinori Shinohara, Y. Kameoka, K. Iwaisako, F. Monma, K. Ohishi, J. Karbach, E. Jäger, K. Sawada, N. Katayama, N. Takahashi, S. Sakaguchi","doi":"10.1084/jem.20191009","DOIUrl":null,"url":null,"abstract":"As a novel type of anticancer reagent, imatinib inhibits not only BCR-ABL oncogenic protein but also LCK in T cells as an off-target, being able to selectively deplete mature T reg cells and thereby evoke effective immune responses to various cancers.","PeriodicalId":23015,"journal":{"name":"The Tokushima journal of experimental medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"58","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Tokushima journal of experimental medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1084/jem.20191009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 58

Abstract

As a novel type of anticancer reagent, imatinib inhibits not only BCR-ABL oncogenic protein but also LCK in T cells as an off-target, being able to selectively deplete mature T reg cells and thereby evoke effective immune responses to various cancers.
酪氨酸激酶抑制剂伊马替尼通过消耗效应调节性T细胞增强肿瘤免疫
作为一种新型的抗癌试剂,伊马替尼不仅可以抑制BCR-ABL致癌蛋白,还可以作为脱靶抑制T细胞中的LCK,能够选择性地消耗成熟T细胞,从而引起对各种癌症的有效免疫反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信